---
title: "Immune Checkpoint Inhibitors Alter Drug-Associated Toxicity Patterns and Timing"
id: "medrxiv-13-immune-checkpoint-blockade-modifies-drug-associated-toxicity-across-phenotypes"
canonical_url: "https://medichelpline.com/clinical-feed/medrxiv-13-immune-checkpoint-blockade-modifies-drug-associated-toxicity-across-phenotypes"
content_type: "clinical_feed_article"
specialty: "Oncology"
source_name: "medRxiv (Clinical Preprints)"
source_url: "https://www.medrxiv.org/content/10.64898/2026.08.31.26361880v1?rss=1"
published_at: "2026-09-02T12:00:00.000Z"
evidence_level: "Verified Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Immune Checkpoint Inhibitors Alter Drug-Associated Toxicity Patterns and Timing
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/medrxiv-13-immune-checkpoint-blockade-modifies-drug-associated-toxicity-across-phenotypes
- **Specialty:** [Oncology](https://medichelpline.com/clinical-feed/oncology.md)
- **Primary Source:** medRxiv (Clinical Preprints)
- **Source URL:** [Original Journal Publication](https://www.medrxiv.org/content/10.64898/2026.08.31.26361880v1?rss=1)
- **Published At:** 2026-09-02T12:00:00.000Z
- **Evidence Rating:** Verified Feed
## Executive GIST (TL;DR)
- Importance: The study evaluated whether **immune checkpoint inhibitors (ICIs)** not only cause immune toxicities themselves but also modify associations between other drugs and adverse events across organs and over time. - Objective: Define the organization of ICI-associated toxicity and determine whether drug-associated adverse events and their onset vary with ICI exposure and checkpoint pathway. - Design and setting: Cross-sectional analysis of deduplicated FDA Adverse Event Reporting System (FAERS) reports from 2016–2025 with analyses performed in 2026. - Dataset: From 13,701,106 deduplicated reports, 2,365,269 cancer-associated reports were identified; 256,940 reports contained an ICI. Median age for cancer reports with observed age was 66 years (IQR 56–75). Sex distribution among cancer reports: 1,031,999 (43.6%) female and 1,003,154 (42.4%) male. - Exposures analyzed: Any reported **ICI** exposure, individual primary-suspect drugs, and checkpoint-pathway exposure. - Main outcomes/measures: Reporting odds ratios (ORs) for adverse events, identification of cross-organ adverse-event communities, adjusted drug × ICI interaction ORs for selected phenotypes (SJS/TEN, DRESS, AGEP, interstitial nephritis, DILI, vomiting), and accelerated failure-time model time ratios for documented onset. - Key findings — adverse-event landscape: Of 3,001 eligible Preferred Terms in cancer-associated reports, 2,091 differed with false discovery rate (FDR) < .05, indicating a structured, cross-organ toxicity landscape associated with ICI exposure. Four cross-organ toxicity communities were identified. - Key drug–phenotype interactions: Of 138 eligible drug–phenotype pairs, 65 showed FDR-significant interactions. Examples reported in the source include amplification of SJS/TEN risk with **moxifloxacin** (interaction OR 101.72; 95% CI, 39.11–264.55), attenuation of SJS/TEN with **enfortumab vedotin** (interaction OR 0.17; 95% CI, 0.13–0.23), and amplification of interstitial nephritis with **omeprazole** (interaction OR 10.35; 95% CI, 7.62–14.05). - Temporal findings: Among 60,324 reports used for time-to-onset analyses, ICI exposure was associated with longer adjusted documented time to onset for five of six phenotypes (time ratios 1.37–1.59). AGEP did not show delayed onset (time ratio 0.99; 95% CI, 0.67–1.46). Temporal associations also varied across checkpoint pathways. - Conclusions: The study supports that **checkpoint blockade** is a modifier of drug-associated toxicity, producing a structured cross-organ toxicity profile, phenotype-specific modification of drug adverse events, and distinct temporal patterns across checkpoint pathways. Authors note these findings motivate longitudinal and mechanistic validation. - Reporting and disclosures: Analyses used openly available FAERS data. Competing interests for one author (Dr Phillips) were reported in the source. Funding sources and data availability statements were provided in the source. - Limitations and next steps: The source recommends longitudinal and mechanistic validation; details about specific limitations of the FAERS-based cross-sectional approach were not reported in the provided text.
## Clinical Analysis & Structured Key Points
Immune Checkpoint Blockade Modifies Drug-Associated Toxicity Across Phenotypes and Time | medRxiv Skip to main content Immune Checkpoint Blockade Modifies Drug-Associated Toxicity Across Phenotypes and Time View ORCID Profile Eric M Mukherjee , View ORCID Profile Amir Asiaee , Dodi Park , View ORCID Profile Matthew S Krantz , View ORCID Profile Cosby A Stone Jr. , View ORCID Profile Michelle Martin-Pozo , View ORCID Profile Elizabeth Jane Phillips doi: https://doi.org/10.64898/2026.08.31.26361880 Eric M Mukherjee Vanderbilt University Medical Center Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Eric M Mukherjee For correspondence: eric.mukherjee{at}vumc.org Amir Asiaee Vanderbilt University Medical Center Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Amir Asiaee Dodi Park Vanderbilt University Medical Center Find this author on Google Scholar Find this author on PubMed Search for this author on this site Matthew S Krantz Vanderbilt University Medical Center Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Matthew S Krantz Cosby A Stone Jr. Vanderbilt University Medical Center Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Cosby A Stone Jr. Michelle Martin-Pozo Vanderbilt University Medical Center Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Michelle Martin-Pozo Elizabeth Jane Phillips Vanderbilt University Medical Center Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Elizabeth Jane Phillips Abstract Info/History Metrics Supplementary material Data/Code Preview PDF Abstract Importance: Immune checkpoint inhibitors (ICIs) produce diverse immune toxicities, but whether checkpoint blockade also modifies associations between other drugs and adverse events is poorly understood. Objective: To define ICI-associated toxicity organization and determine whether drug-associated adverse events and onset vary with ICI exposure and checkpoint pathway. Design and Setting: Cross-sectional analysis of deduplicated FAERS reports from 2016 through 2025; analyses performed in 2026. Participants: Among 13,701,106 deduplicated reports, 2,365,269 were cancer associated and 256,940 contained an ICI. Median age among cancer reports with observed age was 66 years (IQR, 56-75 years); 1,031,999 (43.6%) were female and 1,003,154 (42.4%) were male. Exposures: ICI exposure in any reported drug role, individual primary-suspect drugs, and checkpoint-pathway exposure. Main Outcomes and Measures: Reporting odds ratios (ORs), cross-organ adverse-event communities, adjusted primary-suspect drug x ICI interaction ORs for Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN), drug reaction with eosinophilia and systemic symptoms (DRESS), acute generalized exanthematous pustulosis (AGEP), interstitial nephritis, drug-induced liver injury (DILI), and vomiting (VOM), and accelerated failure-time model time ratios for documented onset. Results: Of 3001 eligible Preferred Terms in cancer-associated reports, 2091 differed at a false discovery rate (FDR) less than .05. Four cross-organ toxicity communities were identified. Of 138 eligible drug-phenotype pairs, 65 had FDR-significant interactions, including moxifloxacin-SJS/TEN amplification (interaction OR, 101.72; 95% CI, 39.11-264.55), enfortumab vedotin-SJS/TEN attenuation (interaction OR, 0.17; 95% CI, 0.13-0.23), and omeprazole-interstitial nephritis amplification (interaction OR, 10.35; 95% CI, 7.62-14.05). Among 60,324 reports contributing to temporal analyses, ICI exposure was associated with longer adjusted documented time to onset for 5 of 6 phenotypes (time ratios, 1.37-1.59) but not AGEP (time ratio, 0.99; 95% CI, 0.67-1.46). Temporal associations also differed across checkpoint pathways. Conclusions and Relevance: ICIs were associated with a structured cross-organ toxicity landscape, phenotype-specific modification of drug-associated adverse events, and distinct temporal patterns across checkpoint pathways. These findings support checkpoint blockade as a modifier of drug-associated toxicity and motivate longitudinal and mechanistic validation. Competing Interest Statement Dr Phillips receives royalties and consulting fees from UpToDate and UpToDate Lexidrug, where she is a Drug Allergy Section Editor and section author, and has received consulting fees from Janssen, Vertex, Verve, Servier, Rapt, and Esperion. Dr Phillips is co-director of IIID Pty Ltd, which holds a patent for HLA-B*57:01 testing for abacavir hypersensitivity, and has a patent pending for detection of HLA-A*32:01 in connection with diagnosing vancomycin-associated drug reaction with eosinophilia and systemic symptoms. She receives no financial remuneration from these patents, neither of which is related to the submitted work. Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: Source data (FAERS) was openly available before the writing of the publication. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable. Yes Data Availability All data produced in the present study are available upon reasonable request to the authors Funder Information Declared National Institutes of Health, https://ror.org/01cwqze88 , U01AI154659 , P50GM115305 , R01HG010863 , R21AI139021 , R01AI152183 , 2 D43 TW010559 National Health and Medical Research Council of Australia PCORI , ME-2023C1-32148 Copyright The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license . Back to top Previous Next Posted September 02, 2026. Download PDF Supplementary Material Data/Code Email Thank you for your interest in spreading the word about medRxiv. NOTE: Your email address is requested solely to identify you as the sender of this article. Your Email * Your Name * Send To * Enter multiple addresses on separate lines or separate them with commas. You are going to email the following Immune Checkpoint Blockade Modifies Drug-Associated Toxicity Across Phenotypes and Time Message Subject (Your Name) has forwarded a page to you from medRxiv Message Body (Your Name) thought you would like to see this page from the medRxiv website. Your Personal Message CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions. Share Immune Checkpoint Blockade Modifies Drug-Associated Toxicity Across Phenotypes and Time Eric M Mukherjee , Amir Asiaee , Dodi Park , Matthew S Krantz , Cosby A Stone Jr. , Michelle Martin-Pozo , Elizabeth Jane Phillips medRxiv 2026.08.31.26361880; doi: https://doi.org/10.64898/2026.08.31.26361880 Share This Article: Copy Citation Tools Immune Checkpoint Blockade Modifies Drug-Associated Toxicity Across Phenotypes and Time Eric M Mukherjee , Amir Asiaee , Dodi Park , Matthew S Krantz , Cosby A Stone Jr. , Michelle Martin-Pozo , Elizabeth Jane Phillips medRxiv 2026.08.31.26361880; doi: https://doi.org/10.64898/2026.08.31.26361880 Citation Manager Formats BibTeX Bookends EasyBib EndNote (tagged) EndNote 8 (xml) Medlars Mendeley Papers RefWorks Tagged Ref Manager RIS Zotero Tweet Widget Facebook Like Google Plus One Subject Areas All Articles Addiction Medicine (614) Allergy and Immunology (896) Anesthesia (327) Cardiovascular Medicine (4772) Dentistry and Oral Medicine (474) Dermatology (407) Emergency Medicine (643) Endocrinology (including Diabetes Mellitus and Metabolic Disease) (1615) Epidemiology (15838) Forensic Medicine (32) Gastroenterology (1195) Genetic and Genomic Medicine (6984) Geriatric Medicine (727) Health Economics (1057) Health Informatics (4988) Health Policy (1427) Health Systems and Quality Improvement (1738) Hematology (581) HIV/AIDS (1336) Infectious Diseases (except HIV/AIDS) (16245) Intensive Care and Critical Care Medicine (1161) Medical Education (663) Medical Ethics (151) Nephrology (721) Neurology (7196) Nursing (364) Nutrition (1074) Obstetrics and Gynecology (1232) Occupational and Environmental Health (1001) Oncology (3575) Ophthalmology (1038) Orthopedics (393) Otolaryngology (446) Pain Medicine (466) Palliative Medicine (139) Pathology (704) Pediatrics (1774) Pharmacology and Therapeutics (733) Primary Care Research (759) Psychiatry and Clinical Psychology (5836) Public and Global Health (9694) Radiology and Imaging (2389) Rehabilitation Medicine and Physical Therapy (1435) Respiratory Medicine (1243) Rheumatology (635) Sexual and Reproductive Health (767) Sports Medicine (577) Surgery (767) Toxicology (107) Transplantation (303) Urology (286)
## Related Clinical Research

- [Pharmacogenomic landscape in Thailand: Array-based PGx profiling and EMR-linked medication exposure](https://medichelpline.com/clinical-feed/pubmed-42545959.md) (DOI: 10.1371/journal.pone.0355201)
- [Explainable Ensemble AI for Melanoma Detection with Leakage-Free Internal Validation](https://medichelpline.com/clinical-feed/medrxiv-0-skin-cancer-classification-using-explainable-artificial-intelligence-with-an.md)
- [Mass General Brigham drops Dana‑Farber from Medicare Advantage network, affecting cancer patients](https://medichelpline.com/clinical-feed/stat-news-0-stat-top-boston-hospitals-clash-over-medicare-advantage-network-after-split.md)
- [Baseline Wastewater Surveillance of Oncogenic Viruses in Southeast Queensland, Australia](https://medichelpline.com/clinical-feed/medrxiv-23-wastewater-surveillance-of-oncogenic-viruses-a-baseline-assessment-in-southeast.md)
- [Electroacupuncture Reduces Central Sensitization in NERD Rats via NGF/TrkA Pathway](https://medichelpline.com/clinical-feed/pubmed-42621713.md) (DOI: 10.13702/j.1000-0607.20260161)

## Navigation
- [← Back to Oncology Feed](https://medichelpline.com/clinical-feed/oncology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.